Nobuaki Matsubara

29PUBLICATIONS
220CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsGeriatrics and gerontologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|May 27, 2026
First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.

|Jul 29, 2025
[177Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan.

Kouji Izumi, Ryuji Matsumoto, Yusuke Ito

|Jun 14, 2025
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

Timothy A Yap, David S P Tan, Anastasios Stathis

|Apr 10, 2025
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.

Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando

|Mar 27, 2025
The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer.

Shu Kato, Kaede Baba, Kanako Mamishin

|Mar 05, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara

Pageof 5

Frequent Collaborators

7 joint publications

Yoichi Naito

4 joint publications

Toru Mukohara

4 joint publications

Hirotsugu Uemura

3 joint publications

Masafumi Ikeda